Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...

If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a ...